SLDB earnings analysis
What we found in SLDB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Solid Biosciences reported a net loss of $56.7 million for Q1 2026, up from a $39.3 million loss in Q1 2025, reflecting increased operational expenses in R&D and G&A. The company continues to advance its gene therapy pipeline for Duchenne muscular dystrophy, Friedreich's ataxia, and catecholaminergic polymorphic ventricular tachycardia, with feasibility and clinical trials ongoing. Cash resources were reported at $380.7 million, which the company believes will sustain operations through 2028.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Q1 Revenue and Loss Numbers
- Reported a net loss of $56.7 million for Q1 2026, compared to a loss of $39.3 million in Q1 2025.
- Increased R&D Spending
- R&D expenses increased to $46.1 million in Q1 2026 from $30.9 million in Q1 2025, mainly due to increased costs for SGT-003.
- Strong Cash Position
- Solid has $380.7 million in cash and cash equivalents, expected to fund operations through the first half of 2028.
- Clinical Trial Progress
- Phase 1/2 trial for SGT-003 shows promising interim results; the trial has dosed 47 participants so far.
- Milestone Payments Fulfilled
- Payments made in stock to FA212 LLC upon reaching development milestones for SGT-212.
- No Debt Reported
- As of March 31, 2026, the company had no outstanding debt.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Patient Enrollment Challenges
- Recruitment for clinical trials may face delays, negatively impacting drug development timelines.
- Regulatory Scrutiny Risks
- Increased scrutiny and potential litigation regarding gene therapy development may impact operational risks.
- Cost Containment and Pricing Pressure
- Legislative measures could impose significant price reductions, affecting revenue generation potential.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.43
What they said about what is next.
Outlook indicates future operational capacity but no specific guidance on revenue or earnings.
The filing reads worse than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SLDB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever